Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oxidized mannan-MUC1 immunotherapy in early breast cancer
ISRCTN71711835Phase 3Completed
- Sponsor
- Prolipsis Medical Center
- Start
- Dec 1997
- Modality
- Vaccines & Immunotherapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
01
Overview
Phase 3 trial of oxidized mannan-MUC1 in breast cancer, sponsored by Prolipsis Medical Center. Primary endpoints: Recurrence rate, Anti-MUC1 antibody response and 1 more. Started Dec 1997; status: completed.
02
Drugs
oxidized mannan-MUC1
03
Conditions
breast cancer
Beyond the preview
Go deeper on ISRCTN71711835.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN71711835.